Cargando…

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer

Androgen deprivation therapy (ADT) is the gold standard treatment in patients with locally advanced or metastatic prostate cancer (PC). Emerging evidence has documented a tight association between ADT and body composition, along with metabolic profile impairment. These alterations might underpin the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corona, Giovanni, Filippi, Sandra, Bianchi, Nicola, Dicuio, Mauro, Rastrelli, Giulia, Concetti, Sergio, Sforza, Alessandra, Maggi, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Sexual Medicine and Andrology 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255402/ https://www.ncbi.nlm.nih.gov/pubmed/32814370 http://dx.doi.org/10.5534/wjmh.200109

Ejemplares similares

Consequences of Anabolic-Androgenic Steroid Abuse in Males; Sexual and Reproductive Perspective
por: Corona, Giovanni, et al.
Publicado: (2022)

Corrigendum: Testosterone Replacement Therapy and Cardiovascular Risk: A Review
por: Corona, Giovanni, et al.
Publicado: (2016)

Testosterone Replacement Therapy and Cardiovascular Risk: A Review
por: Corona G, Giovanni, et al.
Publicado: (2015)

Clinical correlates of enlarged prostate size in subjects with sexual dysfunction
por: Corona, Giovanni, et al.
Publicado: (2014)

Testosterone Deficiency and Risk of Cognitive Disorders in Aging Males
por: Corona, Giovanni, et al.
Publicado: (2021)

Erectile dysfunction and central obesity: an Italian perspective
por: Corona, Giovanni, et al.
Publicado: (2014)

Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction
por: Rastrelli, Giulia, et al.
Publicado: (2019)

Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions
por: Corona, Giovanni, et al.
Publicado: (2014)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Erectile Dysfunction Is a Hallmark of Cardiovascular Disease: Unavoidable Matter of Fact or Opportunity to Improve Men’s Health?
por: Yannas, Dimitri, et al.
Publicado: (2021)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Testosterone therapy: a friend or a foe for the aging men with benign prostatic hyperplasia?
por: Rastrelli, Giulia, et al.
Publicado: (2019)

AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015)

AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)

Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment
por: Wall, Bradley
Publicado: (2016)

Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review
por: Kakarla, Meghana, et al.
Publicado: (2022)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Testosterone Replacement Therapy: Long-Term Safety and Efficacy
por: Corona, Giovanni, et al.
Publicado: (2017)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications
por: Álvarez-Maestro, Mario, et al.
Publicado: (2021)

Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis
por: Corona, Giovanni, et al.
Publicado: (2021)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
por: Ferrari, Nicoletta, et al.
Publicado: (2017)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone
por: Mistretta, Francesco A., et al.
Publicado: (2022)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_43c747b9pkljdr45jr4l8lgfpi